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NOTES AND COMMENTS 
‘Think like a bacterium’: a helpful concept to prolong the 
antibiotic era? 
Clin Microbiol Infect 1998; 4: 177-178 
Bacteria have a remarkable capacity to evolve and adapt 
[ 13. Ths, coupled with the relentless selection pressure 
due to increasing use of antibiotics, had led to the 
prediction that we are now rapidly approaching the end 
of the antibiotic era [2]. We can stdl buy a little time 
by continuing with the traditional approach of using 
antibiotics designed to inhibit bacterial growth du-ectly. 
However, for long-term success radical new ideas for 
combatting infectious diseases are required. One such 
will be briefly explored here: in order to destroy a 
bacterium, it is helpful to think like a bacterium. The 
following discussion will be confined to bacterial 
pathogens, although this type of approach is probably 
equally applicable to viruses, hngi and parasites. 
In an anthropomorphic sense, a bacterium has 
many of the same aspirations as a human being. 
Some of these are especially appropriate to the present 
discussion: 
somewhere to stay 
enough to eat 
a chance to breed tieely 
the ability to give one’s offspring the best chances 
in life 
avoiding natural disasters and troublesome neighbors 
being able to exert a decisive effect at points distant 
&om one’s own location. 
Each of these requirements is capable in theory of 
being turned against the organism, with a resultant 
desired effect of preventing or severely limiting its 
pathogenic potential. As always, the more that is known 
about the precise mechanisms involved in each of 
these activities, the more readily forthcoming will be 
potential inhibitors. 
Infections generally begin with the pathogen gain- 
ing a foothold, often by direct adherence to human 
cells. Either the adhesins-e.g. fimbriae, slime-can 
be targetted directly with antibody or by preventing 
their synthesis, or the receptor, e.g. fibronectin, can be 
masked. Some progress has been made in this direction 
using oligosaccharides to block bindmg sites [3]. 
While it does not seem a practical proposition 
to starve bacteria, they may be persuaded to take in 
substances that appear to be nutrients but are in 
fact toxic. Examples of such illicit transport include 
p-lactams with catechol side-chains, which bacteria 
mistakenly recognize as siderophores [4], and alafosfalin 
The precise mechanisms whea-by bacterial divide 
and separate are not yet understood. Interrupting the 
separation phase would clearly severely limit the ability 
of a pathogen to spread, and so offers a potential 
target for an indirect antibacterial action. The recently 
hscovered staphylococcal organelle, the ‘murosome’ 
[6], is a candidate. 
From a bacterium’s point of view, it is hlghly 
desirable to be able to pass to its progeny acquired genes 
that increase resistance to antibiotics. Deletion of such 
genes would seriously compromise survival. Several 
compounds have been shown to delete R factors in 
vitro, e.g. fluoroquinolones and trirnethoprim; this has 
also been found to occur in vivo [7]. More than 30 
years ago it was demonstrated [8] tlhat the antimalarial 
compound quinacrine selectively killed bacterial cells 
containing R-factors. Surprisingly, little work appears 
to have been done on this aspect, i.e. getting rid of 
existing resistance. 
Bacteria must be able to resist natural defense 
mechanisms. They do t h s  in various ways: by making 
specific toxins such as leukocidin,s, by having anti- 
complementary substances in the cell wall, or by 
producing non-specific viscous substances such as slime 
or alginate that present physical barriers to phagocytes. 
Targetting [9] these protective mechanisms should 
render pathogens much more susceptible to eradication 
by existing defenses. 
Pathogens can have an effect at sites far removed 
from where they are growing, by the production of 
exotoxins. Shorn of such toxins, organisms may be far 
less virulent, or even non-virulent (e.g. Corynebacterium 
diphtheriae). A more common example is the enzyme 
urease; in Proteus spp. this is important in the patho- 
genesis of stones within the urinary tract [lo], and 
in Helicobacter pylori it is crucial [1.1] to the in vivo 
survival of the organism. Inhibition of the action or 
the biosynthesis of such toxic enzymes should modulate 
the pathology for which they are responsible, possibly 
without a requirement for specific measures to eradicate 
the organism. 
It is certain that we will not dispense with the tried 
and tested antibiotics of today within the next few 
decades. However, perhaps by adopting some of the 
strategies mentioned above in parallel with the use of 
conventional therapies, we may be able to prolong their 
useful life. 
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European guidelines for diagnosis and management of 
patients with suspected herpes simplex encephalitis 
Clin Microbiol Infect 1998; 4: 178-180 
Herpes simplex encephahtis (HSE) is probably the most 
severe of the sporadic virus encephalitides. Without 
prompt and specific antiviral treatment, the disease is 
associated with mortality rates exceeding 70% and 
equally high rates of severe morbidity in those who 
survive the acute infection [1,2]. Two major clinical 
trials [3,4] demonstrated that the antiviral drug 
acyclovir, if given early in the course of the disease, 
dramatically reduced both the mortality and morbidity 
of the dsease. 
HSE typically presents as an acute neurologic 
disease associated with an initial prodrome of fever, 
headache and nausea. Altered levels of consciousness 
and a wide variety of non-specific focal neurologic 
signs are also observed. This results in a clinical 
presentation for which there is a wide differential 
diagnosis. In untreated patients HSE is rapidly pro- 
gressive, with brain edema and destruction of areas 
within the brainstem leading to death within 7 to 14 
days. As the new European guidelines on HSE discuss 
[5], the range of clinical presentations is such that the 
establishment of an early etiologic diagnosis demands 
active collaboration between the clinician and the 
diagnostic virus laboratory. 
Whilst the data derived from CT, MRI and EEG 
are important in the investigation of such patients, 
they do not provide information sufficient to allow 
an etiologic hagnosis. The new guidelines stress that 
specific etiologic diagnosis requires that cerebrospinal 
fluid (CSF) be taken (intracranial pressure permitting) 
during the acute stage of the illness. The CSF should 
be examined for HSV DNA using nucleic acid 
amplification techniques. Because the most developed 
and widely applied technology is currently the poly- 
merase chain reaction (PCR), the guidelines concen- 
trate upon this procedure whilst acknowledging that 
emerging target or signal amplification procedures such 
as NASBA, LCR or B-DNA [6] may, in time, prove 
equally useful. For PCR, the required sensitivity is 
believed to be of the order of 10 or less genome 
equivalents per 10 pL of CSF [7].  As approximately 
5% of cases of HSE are due to HSV type 2, the PCR 
test protocol should also be designed to detect both 
HSV type 1 and HSV type 2 DNA. Both single and 
nested PCR procedures have been found satisfactory. 
Experience accumulated over 6 years shows that HSV 
DNA is usually detectable at the onset of neurologic 
symptoms and that the PCR remains positive for at  
least 5 days after the start of acyclovir therapy. 
Complementary to the detection of HSV DNA in 
CSF is the detection of a specific intrathecal humoral 
immune response to the virus. Over the course of the 
infection, DNA becomes undetectable in CSF, and a 
strong and persistent intrathecal immune response 
develops. A variety of formulae, evaluated by the 
European Concerted Action of Virus Meningitis and 
Encephalitis [8] ,  can be used to quantifj this immune 
response. This is achieved by the detection of an 
increased CSF/serum quotient for HSV antibody, 
adjusted for CSF/blood-brain barrier integrity. In 
